Abstract
Background Currently available treatments for Parkinson’s disease (PD) do not slow clinical progression nor target alpha-synuclein, the main pathology associated with the disease.
Objective The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. The study rationale, design, and baseline characteristics of enrolled subjects are presented here.
Methods The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1500 mg or 4500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40–80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g. resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson’s Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations.
Results Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. The mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society – Unified Parkinson’s Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS Total score [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) also showed a similar severity in MDS-UPDRS scores (e.g. MDS-UPDRS Total score [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve).
Conclusions The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD.
Trial Registration NCT03100149
Competing Interest Statement
Gennaro Pagano is a full-time employee of F. Hoffmann-La Roche. Frank G Boess is a full-time employee of F. Hoffmann-La Roche. Kirsten I Taylor is a a full-time employee and shareholder of F. Hoffmann-La Roche. Benedicte Ricci is a full-time employee of F. Hoffmann-La Roche. Brit Mollenhauer reports personal fees from Roche, and served on the advisory board for Roche during the conduct of the study. Werner Poewe reports personal fees from Roche Pharmaceuticals during the conduct of the study; personal fees from Affiris, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Neurocrine, Roche, Takeda, UCB, STADA and Zambon, outside of the submitted work. Anne Boulay was an employee of F. Hoffmann-La Roche, during the study. Judith Anzures-Cabrera is a full-time employee and shareholder of F. Hoffmann-La Roche. Annamarie Vogt is a full-time employee of F. Hoffmann-La Roche. Maddalena Marchesi is a full-time employee of F. Hoffmann-La Roche. Anke Post was an employee of F. Hoffmann-La Roche from 1.1.2017-30.11.2019. Tania Nikolcheva is a full-time employee and shareholder of F. Hoffmann-La Roche. Gene G Kinney is an officer, director and shareholder of Prothena Biosciences Inc, received funding for the work from F. Hoffmann-La Roche, and has a patent for Monitoring Immunotherapy Of Lewy Body Disease From Constipation Symptoms licensed to F. Hoffmann-La Roche. Wagner M Zago is an employee, officer and shareholder of Prothena Biosciences Inc, received funding for the work from F. Hoffmann-La Roche, and has a patent for Treatment Of Parkinson's Disease licensed to F. Hoffmann-La Roche. Daniel K Ness has nothing to disclose. Hanno Svoboda is an employee and shareholder of F. Hoffmann-La Roche. Markus Britschgi is a full-time employee and shareholder of F. Hoffmann-La Roche. Susanne Ostrowitzki is an employee of F. Hoffmann-La Roche and stock owner in the company. Tanya Simuni reports grants from NINDS, MJFF, Parkinson's Foundation, grants from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Abbvie, IMPAX, Prevail, other from Acadia, Accorda, Adamas, Allergan, Amneal, Aptinyx, Denali, General Electric (GE), Kyowa, Neuroderm, Neurocrine, Sanofi, Sinopia, Sunovion, Roche, Takeda, Voyager, US World Meds, during the conduct of the study. Kenneth Marek reports grants and personal fees from Michael J Fox Foundation, personal fees from Roche, Takeda, Sanofi, Biohaven, GEHC, Inhibikase, Invicro, Hemacure, Neuron23, LTI and alkahest, outside the submitted work. Martin Koller was an employee of Prothena Biosciences Inc, during the study and received stock options during this time. Jeffrey Sevigny was an employee of F. Hoffmann-La Roche, during the study. Rachelle Doody is a full-time employee of Roche/Genetech and holds stocks and stocks options in the company. Paulo Fontoura is a full-time employee and shareholder of F. Hoffmann-La Roche. Daniel Umbricht is a former employee and shareholder of F. Hoffmann-La Roche. Azad Bonni is a full-time employee and shareholder of F. Hoffmann-La Roche.
Clinical Trial
NCT3100149
Funding Statement
The PASADENA study was funded by F. Hoffmann-La Roche Ltd. PPMI, a public-private partnership, is sponsored by the Michael J. Fox Foundation (MJFF) for Parkinson's Research and is co-funded by MJFF, AbbVie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biogen Idec, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Denali Therapeutics Inc., 4D Pharma Plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Genentech Inc, GlaxoSmithKline, Golub Capital BDC, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Sanofi Genzyme, Servier, Takeda, Teva Pharmaceutical Industries Ltd, UCB, Verily Life Sciences and Voyager Therapeutics. Industry partners contribute to PPMI through financial and in-kind donations and have a lead role in providing feedback on study parameters through the Partners Scientific Advisory Board (PSAB). Through close interaction with the study, the PSAB is positioned to inform the selection and review of potential progression markers that could be used in clinical testing.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants were identified for potential recruitment using site-specific recruitment plans prior to consenting to take part in this study. Recruitment materials for participants had received Institutional Review Board or Ethics Committee approval prior to use. The following Institutional Review Boards ruled on ethics of the PASADENA study: Ethikkommission der Medizinischen Universität Innnsbruck, Innsbruck, Austria; Comité de Protection des Personnes (CPP) Ouest IV, Nantes, France; Ethikkommission der Universität Leipzig and Geschäftsstelle der Ethikkommission an der medizinischen Fakultät der Universität Leipzig, Leipzig, Germany; Ethikkommission der Fakultät für Medizin der Technischen Universität München, München, Germany; Ethikkommission der Universität Ulm (Oberer Eselsberg), Ulm, Germany; Landesamt für Gesundheit und Soziales Berlin and Geschäftsstelle der Ethik-Kommission des Landes Berlin, Berlin, Germany; Ethikkommission des FB Medizin der Philipps-Universität Marburg, Marburg, Germany; Ethikkommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen, Tübingen, Germany; Ethikkommission an der Med. Fakultät der HHU Düsseldorf, Düsseldorf, Germany; Ethikkommission der LÄK Hessen, Frankfurt, Germany; CEIm Hospital Universitari Vall d'Hebron, Barcelona, Spain; Copernicus Group Independent Review Board, Puyallup, Washington, USA; Western Institutional Review Board, Puyallup, Washington, USA; The University of Kansas Medical Center Human Research Protection Program, Kansas City, Kansas, USA; Oregon Health & Science University Independent Review Board, Portland, Oregon, USA; Northwestern University Institutional Review Board, Chicago, Illinois, USA; Spectrum Health Human Research Protection Program, Grand Rapids, Michigan, USA; The University of Vermont Committees on Human Subjects, Burlington, Vermont, USA; Beth Israel Deaconess Medical Center Committee on Clinical Investigations, New Procedures and New Forms of Therapy, Boston, Massachusetts, USA; Vanderbilt Human Research Protection Program Health, Boston, Massachusetts, USA; Vanderbilt Human Research Protection Program Health, Nashville, Tennessee, USA; University of Maryland, Baltimore Institutional Review Board, Baltimore, Maryland, USA; University of Southern California Institutional Review Board, Los Angeles, California, USA; Columbia University Medical Center Institutional Review Board, New York, New York, USA; University of Southern California San Francisco Institutional Review Board, San Francisco, California, USA; University of Pennsylvania Institutional Review Board, Philadelphia, Philadelphia, USA; HCA - HealthOne Institutional Review Board, Denver, Colorado, USA. All Institutional Review Boards gave ethical approval of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to individual patient-level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (http://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/data). For up-to-date information on the study, visit ppmi-info.org.
